Our People

Yuichi Kawano

Director

Dr. Kawano has more than 35 years of experience in R&D and business development at Otsuka Pharmaceutical Factory, Inc. (OPF). Following his role as a director of the R&D center of OPF, he became COO at Diatranz Otsuka Limited (DOL) in 2014 and 2015 and contributed to the product development in New Zealand. He has been an Executive Director of OPF since 2022 and rejoined to DOL in 2023 as a Director.

Dr. kawano received his M.S. in Agricultural Chemistry from University of Osaka Prefecture, and Ph.D. in Clinical Physiology from Karolinska Institute.

Takayuki Hasegawa

Director & Chief Executive Officer

Mr Hasegawa became a Director and CEO of Diatranz Otsuka Limited in Jan of 2018. He also holds the position of Lead for US Operation of Otsuka Pharmaceutical Companies (U.S) and manages the activities of DOLs U.S. branch in Illinois. Mr. Hasegawa joined Otsuka Pharmaceutical Factory in 1993 and has more than 20 years experiences in the field of business development and marketing.

Mr. Hasegawa received his B.S in Bio Biochemistry from Meiji Pharmaceutical University.

Shaun Wynyard

Director & Chief Operating Officer

Mr. Wynyard has been with Diatranz Otsuka Limited (DOL) since 2006 starting in the Molecular Diagnostic Laboratory where he helped develop DOLs xenosafety program in support of early phase clinical trials. He is skilled in the areas of molecular biology, method development, assay validation and compliance with medical laboratory best practices including ISO standard 15189:2012. Mr. Wynyard has gained in-depth knowledge and experience across all aspects of the company’s operations and has been managing and leading the business operations in NZ since November 2015 as General Manager before becoming a Director and COO in 2018.

Mr. Wynyard holds a B.Sc(Tech) in Biology from Waikato University, as well as an M.Sc. in Biology and an MBA from the University of Auckland.

Shinichi Matsumoto

Chief Scientific Officer

Dr. Matsumoto is a Senior Scientific Advisor at Otsuka Pharmaceutical Factory Inc. He has extensive experience in the transplantation field with his research focused on isolated pancreatic islet transplantation from both human and porcine sources. He has published more than 300 scientific papers and continues to be active in numerous societies and organisations within the xenotransplantation community.

Dr. Matsumoto received his M.D. and Ph.D. from Kobe University.